Series A brings $20mm to Exosome Diagnostics
Cancer testing start-up Exosome Diagnostics Inc. (ED) raised $20mm through its Series A round co-led by NGN Capital and Forbion Capital Partners, which each also contribute members to Exosome's board.
- In Vitro Diagnostics
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Venture Financing
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.